Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

S-adenosylmethionine and depression.

Minh Nguyen, Angel Gregan

    Australian Family Physician
    |June 5, 2002
    PubMed
    Summary
    This summary is machine-generated.

    S-adenosylmethionine (SAMe) is a safe and effective supplement for treating mild to moderate depression. It offers an alternative or complementary therapy to traditional antidepressants, with fewer side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Design of an artificial intelligence model to screen spontaneous speech to detect Alzheimer's Disease.

    PLOS digital health·2026
    Same author

    A proteogenomic RNA processing mechanism drives sex differences in meningioma.

    Research square·2026
    Same author

    Constrained Design of a Binary Instrument in a Partially Linear Model.

    Observational studies·2026
    Same author

    Timing of Tourniquet Release: A Prospective Randomized Trial.

    Hand (New York, N.Y.)·2026
    Same author

    Somatic cancer variants enriched in Alzheimer's disease microglia-like cells drive inflammatory and proliferative states.

    Cell·2026
    Same author

    Estimation of Costs Related to the Management of Herpes Zoster and its Complications in Vietnam: A Medical Chart Review.

    Infectious diseases and therapy·2026
    Same journal

    Occupational violence and staff safety in general practice.

    Australian family physician·2018
    Same journal

    You should get that mole checked out: Ethical and legal considerations of the unsolicited clinical opinion.

    Australian family physician·2018
    Same journal

    Understanding the decision to commence a dose administration aid.

    Australian family physician·2018
    Same journal

    Psychological distress and risky sexual behaviours among women aged 16-25 years in Victoria, Australia.

    Australian family physician·2018
    Same journal

    A mixed-methods feasibility study of routinely weighing patients in general practice to aid weight management.

    Australian family physician·2018
    Same journal

    The Australian Mid-West Coastal Marine Wound Infections Study.

    Australian family physician·2018
    See all related articles

    Area of Science:

    • Nutritional Psychiatry
    • Pharmacology
    • Clinical Psychology

    Background:

    • Depression is a prevalent mental health condition frequently managed in clinical settings.
    • Existing antidepressant medications often present with undesirable side effects, necessitating exploration of alternatives.
    • There is a clinical need for treatments with improved safety profiles.

    Purpose of the Study:

    • To comprehensively review existing clinical evidence regarding S-adenosylmethionine (SAMe) for depression.
    • To evaluate the safety and efficacy of SAMe in managing depressive symptoms.

    Main Methods:

    • Systematic review of clinical trials and observational studies.
    • Analysis of data on SAMe's effectiveness in reducing depression scores.
    • Assessment of reported adverse events and safety data associated with SAMe use.

    Related Experiment Videos

    Main Results:

    • Clinical studies indicate that SAMe is a safe and effective treatment for mild to moderate depression.
    • SAMe, a naturally occurring molecule, demonstrates significant antidepressant properties.
    • Evidence suggests a favorable side effect profile compared to conventional antidepressants.

    Conclusions:

    • SAMe shows promise as a therapeutic option for depression.
    • Further research is warranted to establish SAMe's role as a first-line depression treatment.
    • Healthcare providers should consider SAMe's safety and efficacy for patients seeking complementary or alternative depression therapies.